Winnipeg, Manitoba – October 16, 2025 – TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”), a biotechnology company developing innovative bacteriophage solutions for animal and human health, is pleased to announce that W.L.T. Distributors Inc. (WLT), a Manitoba-based agricultural supply company, has agreed to distribute OvaPhage across Canada. OvaPhage is a bacteriophage product for eggs designed to reduce Salmonella load on egg shells, improving food safety and decreasing reliance on harsh chemical cleaning solutions.  

 

This announcement follows Cytophage’s recent receipt of Health Canada’s Letter of No Objection (LONO) for the sale of OvaPhage. The LONO represents a key regulatory milestone for Cytophage and marks one of the first commercial bacteriophage products of its kind that will be available for sale in Canada.

 

“Cytophage is excited to have WLT Distributors on board to sell OvaPhage in Canada,” said Dr. Steven Theriault, Chief Executive Officer of Cytophage Technologies. “Our strength lies in developing scientifically advanced bacteriophage solutions. WLT Distributors bring decades of market knowledge, trusted relationships, and on-the-ground expertise to help farmers adopt novel products that improve animal health and production efficiency. It’s an ideal partnership. WLT provides efficient, cost-effective marketing and distribution services for agricultural and feed products, sharing Cytophage’s vision of improving food safety and sustainability through leading-edge technologies.”

 

Through significant work in the Cytophage laboratories and in collaboration with Canadian egg producers, the Company is now ready to move forward with the commercialization and distribution of OvaPhage.  As Cytophage completes work on packaging and labelling, WLT has identified early adopters willing to try this newly commercialized product.  

 

“We have been following Cytophage’s progress from R&D to commercialization and are thrilled to work with their team on sales and distribution.  Given the challenges our industry faces today, it is critical we use innovative products that are both sustainable now and adaptable well into the future” said James Hokanson, Chief Operating Officer of WLT.

 

According to Statistics Canada, the egg industry in Canada produced over 915 million dozen eggs in 2024 (Stats Canada Report).  The Company is looking forward to working with WLT to prepare OvaPhage for the market, ensuring the product meets the needs of prospective customers.  Together, Cytophage and WLT aim to make OvaPhage broadly accessible to egg producers across Canada, contributing to sustainable food production in poultry operations.

   

About WLT

 

WLT, headquartered in Manitoba, has been sourcing and supplying feed ingredients and agricultural products to farms around the world for more than 40 years. WLT is recognized for its commitment to quality, customer service, and its ability to bridge the gap between product manufacturers and on-farm applications.

 

WLT's team has a combined 50 years of experience selling in the poultry industry in Canada. WLT is connected with the decision makers of Canada's egg producers, processors, hatcheries, and marketing boards. 

 

About Cytophage

   

Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature’s version of antibiotics.  

 

Cytophage is improving bacteria’s natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR).  

 

The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.  

 

Cytophage is using a de-risked and patented technology to advance innovative and cost competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.  

 

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

   

For further information please contact:  

Heather Medwick, Chief Operating Officer

heather@cytophage.com

Cytophage Investor Alerts: https://cytophage.com/subscribe

 

Cautionary Statement on Forward-Looking Information  

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

 

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.